Jason Adair Sells 13,548 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 13,548 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $507,101.64. Following the completion of the transaction, the insider directly owned 184,174 shares in the company, valued at approximately $6,893,632.82. This represents a 6.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Jason Adair also recently made the following trade(s):

• On Monday, December 1st, Jason Adair sold 693 shares of Liquidia stock. The stock was sold at an average price of $32.19, for a total value of $22,307.67.
• On Tuesday, November 18th, Jason Adair sold 35,656 shares of Liquidia stock. The shares were sold at an average price of $30.03, for a total transaction of $1,070,749.68.
• On Monday, October 27th, Jason Adair sold 692 shares of Liquidia stock. The stock was sold at an average price of $22.93, for a total transaction of $15,867.56.

Liquidia Price Performance

Shares of NASDAQ:LQDA opened at $39.99 on Thursday. The firm has a market cap of $3.48 billion, a price-to-earnings ratio of -27.77, a P/E/G ratio of 0.65 and a beta of 0.48. The firm has a fifty day moving average price of $32.41 and a 200 day moving average price of $25.68. Liquidia Corporation has a fifty-two week low of $11.26 and a fifty-two week high of $40.53. The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.41. The business had revenue of $54.34 million for the quarter, compared to analysts’ expectations of $18.86 million. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The business’s revenue was up 1106.7% on a year-over-year basis. As a group, sell-side analysts expect that Liquidia Corporation will post -1.51 earnings per share for the current fiscal year.

Key Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Recent patent and court wins reduce execution and IP risk for Liquidia’s inhaled treprostinil program, supporting upside potential for commercialization. Seeking Alpha – Patent Update
• Positive Sentiment: Analyst sentiment has been upgraded recently (multiple firms raising targets and issuing Buy/Strong Buy ratings), which can attract fresh capital and lend support to the rally. Benzinga – Analyst Expectations
• Positive Sentiment: Short interest fell materially in December (reported ~18% decline), lowering potential downward pressure from short sellers and reducing immediate squeeze/volatility risk. MarketBeat – Short Interest & Court Coverage
• Neutral Sentiment: Analyst/industry write-ups note the company has won many patent battles but caution the “war is not yet won,” signaling that legal/IP progress is positive but some uncertainties remain. Seeking Alpha – Balanced Take
• Negative Sentiment: Large, coordinated insider selling occurred on Jan. 12: CEO Roger Jeffs (66,610 sh, ~$2.49M), CFO Michael Kaseta (36,932 sh, ~$1.38M), General Counsel Russell Schundler (27,289 sh, ~$1.02M) and several other insiders (collectively selling millions of dollars of stock). While insiders still retain significant stakes, the volume and scale of sales may be viewed as profit‑taking and can weigh on sentiment. MarketBeat – Insider Trades

Institutional Trading of Liquidia

Several institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Liquidia by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after acquiring an additional 1,700 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Liquidia by 10.7% in the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock worth $12,703,000 after purchasing an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Liquidia by 15.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after buying an additional 16,022 shares during the period. Rhumbline Advisers grew its stake in Liquidia by 6.0% in the 1st quarter. Rhumbline Advisers now owns 85,463 shares of the company’s stock worth $1,261,000 after acquiring an additional 4,811 shares in the last quarter. Finally, Ballentine Partners LLC increased its position in shares of Liquidia by 10.2% during the second quarter. Ballentine Partners LLC now owns 12,139 shares of the company’s stock worth $151,000 after acquiring an additional 1,119 shares during the period. Institutional investors own 64.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on LQDA shares. Wells Fargo & Company started coverage on Liquidia in a report on Monday, October 20th. They set an “overweight” rating and a $31.00 price objective on the stock. Raymond James Financial reaffirmed a “strong-buy” rating and set a $47.00 price target on shares of Liquidia in a research note on Tuesday, November 4th. HC Wainwright lifted their price objective on shares of Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Needham & Company LLC boosted their target price on shares of Liquidia from $36.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $39.67.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).